AstraZeneca PLC — Board/Management Information 2020

Jul 16, 2020

National Storage Mechanism | Additional information

RNS Number : 1169T

AstraZeneca PLC

16 July 2020

16 July 2020 07:00 BST

Director Declaration

AstraZeneca PLC (the Company) today announced that Pascal Soriot, Chief Executive Officer of the Company, has been appointed as an independent Non-Executive Director of CSL Limited (ASX:CSL; USOTC:CSLLY), to be effective from 19 August 2020.

This announcement is made pursuant to Listing Rule 9.6.14 R (2).

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RDNXELFFBDLZBBX